TY  - GEN
N2  - For obvious reasons, oncologic care has worked to move away from the toxic inpatient intravenous chemotherapy treatment strategies and toward the development of more convenient oral therapies that patients self-manage at home. Mercaptopurine and methotrexate were the first oral chemotherapy agents approved in 1953. Since that time, the use and development of new oral agents has increased in cancer care and has resulted in a shift in the way cancer care is provided.  In 2012, up to 35% of the new oncology drugs were oral agents. As of 2013, more than 50 oral anticancer drugs had obtained Federal Drug Administration (FDA) approval and were available on the market. Due to the recent increase in the quantity of FDA approved oral therapy regimens for the treatment of cancer, drug choice has transitioned from infused or injectable medications to oral agents. Although all of these barriers exist, the focus of this project was to evaluate the systemic barriers that providers and staff have to an optimal oral chemotherapy process.
DO  - 10.6083/m4kp81pd
DO  - DOI
AB  - For obvious reasons, oncologic care has worked to move away from the toxic inpatient intravenous chemotherapy treatment strategies and toward the development of more convenient oral therapies that patients self-manage at home. Mercaptopurine and methotrexate were the first oral chemotherapy agents approved in 1953. Since that time, the use and development of new oral agents has increased in cancer care and has resulted in a shift in the way cancer care is provided.  In 2012, up to 35% of the new oncology drugs were oral agents. As of 2013, more than 50 oral anticancer drugs had obtained Federal Drug Administration (FDA) approval and were available on the market. Due to the recent increase in the quantity of FDA approved oral therapy regimens for the treatment of cancer, drug choice has transitioned from infused or injectable medications to oral agents. Although all of these barriers exist, the focus of this project was to evaluate the systemic barriers that providers and staff have to an optimal oral chemotherapy process.
AD  - Oregon Health and Science University
T1  - Quality improvement for oral oncolytics
DA  - 2017
AU  - Hartman, Amy
L1  - https://digitalcollections.ohsu.edu/record/7644/files/Hartman.Amy.2017.pdf
PB  - Oregon Health and Science University
PY  - 2017
ID  - 7644
L4  - https://digitalcollections.ohsu.edu/record/7644/files/Hartman.Amy.2017.pdf
KW  - Medication Adherence
KW  - Drug Therapy
KW  - Neoplasms
KW  - Mouth Neoplasms
KW  - drug administration
TI  - Quality improvement for oral oncolytics
Y1  - 2017
L2  - https://digitalcollections.ohsu.edu/record/7644/files/Hartman.Amy.2017.pdf
LK  - https://digitalcollections.ohsu.edu/record/7644/files/Hartman.Amy.2017.pdf
UR  - https://digitalcollections.ohsu.edu/record/7644/files/Hartman.Amy.2017.pdf
ER  -